The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...

Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Amneal Pharmaceuticals (AMRX) reports results for the quarter ended December 2024. While this widely-known consensus ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.53 billion, has been positioning itself for a new phase of multi-year growth ...

Amneal Pharmaceuticals (NYSE:NASDAQ:AMRX), a commercial-stage biopharmaceutical company with a market capitalization of $2.53 billion, has been positioning itself for a new phase of multi-year ...

In trading on Monday, shares of Amneal Pharmaceuticals Inc (Symbol: AMRX) crossed below their 200 day moving average of $7.76, changing hands as low as $7.68 per share. Amneal Pharmaceuticals Inc ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today ...

Let’s dig into the relative performance of Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers as we unravel the ...

It is worth considering Amneal Pharmaceuticals (AMRX), which belongs to the Zacks Medical - Drugs industry. When looking at the last two reports, this pharmaceutical company has recorded a strong ...